We describe a patient who was admitted with uncontrolled thyrotoxicosis and carbimazole induced neutropenia. She required 80 mg of carbimazole daily. The patient declined radio-iodine treatment because she had a little child and wished to have thyroid surgery. She received four doses of filgrastim (Granulocyte-colony stimulating factor) which maintained the neutrophil count within a reasonable level while she continued to receive carbimazole to prepare her for surgery. After a curative subtotal thyroidectomy and discontinuation of the carbimazole, the patient's white cell count remained normal. Subsequently the patient was euthyroid on levothyroxine replacement. Carbimazole should always be discontinued if neutropenia occurs but this case demonstrates that in exceptional circumstances filgrastim can be an effective therapy while continuing carbimazole in the short term.
Case report
A 24 year old woman was admitted with symptoms of thyrotoxicosis. She was found to have warm sweaty hands, a tachycardia, uncontrolled thyrotoxicosis and low white cell count.
Her past history showed:
Thyrotoxicosis (Graves' disease) diagnosed five years earlier with carbimazole treatment for two years in the post partum period, followed by a relapse after six months;
Polycystic ovarian syndrome diagnosed at the age of 17 years; A low normal white cell count and neutrophil count while on carbimazole and iron deficiency anaemia treated with iron tablets in the past Her medications included carbimazole 60 mg daily and propranolol 10 mg tds. On examination she had a smooth, symmetrical non tender goitre and a heart rate of 116/minute.
Her blood results showed : TSH (thyroid stimulating hormone) not detectable (normal 0.27-4.7 mU/l), FT4 (free thyroxine) 89.4 pmol/l (normal 12-22 ) and T3 (triiodothyronine) 8.4 nmol/l (normal 1.3-3.1); Haemoglobin 11.4g/dl (normal 11.5-16.5), MCV (mean corpuscular volume) 70.3 fl (normal 76-100), WCC 2.3 × 10 9 /l (normal 4-11) and neutrophil count 0.8 × 10 9 /l (normal 1.7-7.5).
The patient was advised to discontinue carbimazole and have radioactive iodine therapy. However, she declined radioactive iodine therapy because she had a three year daughter at home and the treatment would require her to avoid prolonged close contact with her daughter for 21 days. This was not acceptable to her as she was unable to arrange care for her child and she could not face the separation psychologically. She was fully informed of the possible risks of carbimazole therapy and understood the risks but wished to continue the treatment and to be prepared for thyroid surgery.
The patient was apyrexial. A consultant haematologist with special expertise in filgrastim treatment was asked to give advice about continuing carbimazole therapy and using filgrastim as support in the short term. She was given G-CSF (Granulocyte colony stimulating factor) 300 mcg/day s/c on two consecutive days. The white cell count rose to 9.6 × 10 9 /l with a neutrophil count of 7.4 × 10 9 /l (see chart). The white cell count continued to vary between 2.8 to 3.6 × 10 9 /l and the neutrophil count varied between 1.6 to 2.3 × 10 9 /l over the next few days. The carbimazole dose was increased to 80 mg and propranolol was changed to long acting propranolol 80 mg daily. Two weeks later the patient received a third dose of G-CSF as the neutrophil count dropped to 1.1×10 9 /l (white cell count ×10 9 /l was 2.2). Three days later her WCC was 5.7 × 10 9 /l and neutrophil 4.5 × 10 9 /l. Her thyroid status improved on 80 mg of carbimazole daily and the dose was reduced to 60 mg daily. At the time of discharge her thyroid function tests showed TSH not detectable, FT4 25.4 pmol/l and T3 3.0 nmol/l.
The patient was discharged on 60 mg of carbimazole and long acting propranolol 80 mg daily. The patient was referred for an urgent subtotal thyroidectomy. Her haemoglobin was 10.4 g/dl with MCV 71fl.
On discharge the patient had a full blood count performed on alternate days with arrangements made for her to receive G-CSF if the neutrophil count dropped to < 1.5 × 10 9 /l. A week later the patient's thyroid function had improved considerably. Her blood results showed; TSH not detectable, FT4 18.0 pmol/l and T3 3.0 nmol/l. Two weeks later the patient's white cell count was 2.4 × 10 9 /l with a neutrophil count of 1.2 × 10 9 /l. The patient received another dose of G-CSF. The carbimazole dose was gradually reduced to 40 mg daily with monitoring of the thyroid function. Table 1 White cell count and thyroid profile on different days following admission.
Once euthyroid, the patient underwent a subtotal thyroidectomy. The carbimazole was discontinued and replacement therapy with levothyroxine was started. Six weeks after surgery her white cell count was 4.3 x 10 9 /l and neutrophil 2.7 × 10 9 /l. Her haemoglobin level was 12.9 g/dl with MCV of 78.4 fl . Thyroid function test results showed TSH 12.28 mU/l, FT4 18.2 pmol/l and T3 1.8 nmol/l. She was on levothyroxine 150 mcg/day and iron tablets. The dosage of levothyroxine was increased to 175 mcg/day. Her white cell count and neutrophil count have remained normal ever since.
One year later the patient had a miscarriage. She was treated with metformin 500 mg tds for polycystic ovarian syndrome. Subsequently the patient became pregnant and gave birth to a healthy baby. She is currently taking levothyroxine 225 mcg daily (body mass index 34 kg/m 2 ) and her latest thyroid function tests were normal. The white cell count was also normal.
Discussion
Carbimazole is known to cause agranulocytosis or aplastic anaemia [1] in 1 to 3 out of 1000 patients which usually occurs within the first 3 months of treatment [2] but can occur later on as well [3] .
We report the first patient who received carbimazole and G-CSF simultaneously. The CSM (Committee on Safety of Medicines, UK) warns that carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia. The patient was advised to do this and receive radioactive iodine but she did not agree and wished to have thyroid surgery. However surgery could not be undertaken while she was thyrotoxic and so the possibility of continuing the carbimazole while treating her with filgrastim was considered. Thus simultaneously with carbimazole we administered G-CSF (Filgrastim) to maintain the neutrophil count > 1.5 × 10 9 /l. From a search of the literature this appears to be the first report of a patient who had G-CSF while on carbimazole. There have been a few reports where carbimazole was withdrawn because of agranulocytosis or aplastic anaemia followed by GCSF therapy [4, 5] .
Filgrastim is a human Granulocyte colony stimulating factor (G-CSF), produced by recombinant DNA technology. Colony stimulating factors are glycoproteins which act on haematopoietic cells [6, 7] by binding to specific cell surface receptors and stimulating proliferation, differential commitment and some end-cell functional activation. Filgrastim regulates the production and function of neutrophils. Filgrastim controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase.
We believe that therapy with G-CSF while continuing with carbimazole should only be given in exceptional circumstances and under very close expert supervision. Apart from exceptional circumstances we would like to emphasise that carbimazole should always be discontinued if neutropenia occurs and then radioiodine is usually the treatment of choice. If agranulocytosis occurs, if the patient is unwell or has signs of infection, then carbimazole should be discontinued without exception.
